Skip to search formSkip to main contentSkip to account menu

Iodine I 131 Rituximab

Known as: (131)I-Rituximab, 131I-Rituxan 
A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning…
2015
2015
Doxorubicin enhances (131)I-rituximab induced cell death in Raji cells.
AIM There are various therapeutic modalities of treatment for non-Hodgkin's lymphoma, but with certain limitations, hence… 
2013
2013
Prediction of non-Hodgkin's lymphoma refractory to repeated radioimmunotherapy with (131)I-rituximab using (18)F-FDG PET/CT after the first radioimmunotherapy.
2012
2012
Standard Operating Procedure for In-house Preparation of 131I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
A Standard Operating Procedure (SOP) has been formulated for in-house preparation, quality control, dispensing and administration… 
2009
2009
A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.
The aim of this study was to develop a safe and simple radiolabeling and purification procedure for high-dose (131)I-rituximab… 
2009
2009
[In vitro cytotoxicity of 131I-Rituximab against B-cell lymphoma cells].
OBJECTIVE To study the specific cytotoxicity of (131)I-Rituximab against CD20-positive B-cell lymphoma cells. METHODS Rituximab… 
Review
2009
Review
2009
Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience.
: Determination of individual pharmacokinetics in patients undergoing radiopharmaceutical therapy is essential to define critical… 
2006
2006
[Biological response of B-cell lymphoma cells in vitro to 131I-rituximab].
OBJECTIVE To study the biological response of B-cell lymphoma cells positive for CD20 expression to (131)I-labeled rituximab… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)